NewsBenzingaBTIG ribadisce il giudizio Buy su Denali Therapeutics, mantiene il target di prezzo di 39 dollari BTIG ribadisce il giudizio Buy su Denali Therapeutics, mantiene il target di prezzo di 39 dollari Benzinga 2026.11.04 09:59 (GMT+0) Open on Benzinga Other news What Are Wall Street Analysts' Target Price for Lumentum Holdings Stock? Texas Pacific Land Stock: Analyst Estimates & Ratings Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday